Clinical Trial for HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) and Colorectal Cancer.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer

Sex

Male or Female

Age

18+ years

Healthy participants

Visit ClinicalTrials.gov for more information

Eligibility criteria

Inclusion criteria

Be receiving tucatinib as a study intervention and deriving clinical benefit without evidence of disease progression (as determined by the investigator) in a tucatinib Parent Study.
Agree to follow the reproductive criteria.
Be willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in this protocol.
Be capable of giving signed informed consent.

Exclusion criteria

Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
Current use of any prohibited concomitant medications(s) or unwillingness or inability to use a required concomitant medication(s).
Participants not previously enrolled or who have discontinued study intervention or who were randomized in the control arm in a Parent Study.

Study overview

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.

Join PfizerConnect

Tucatinib Continuation Study

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Join PfizerConnect

Tucatinib Continuation Study

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?